Sanctuary Advisors LLC Sells 19,801 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Sanctuary Advisors LLC cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 17.2% in the first quarter, HoldingsChannel reports. The firm owned 94,996 shares of the biopharmaceutical company’s stock after selling 19,801 shares during the period. Sanctuary Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $2,352,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CPRX. State Street Corp grew its position in shares of Catalyst Pharmaceuticals by 7.8% during the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock worth $161,224,000 after buying an additional 502,235 shares in the last quarter. Deerfield Management Company L.P. increased its stake in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after buying an additional 2,095,291 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after acquiring an additional 333,100 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Catalyst Pharmaceuticals by 21.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,996,297 shares of the biopharmaceutical company’s stock valued at $69,933,000 after acquiring an additional 538,128 shares in the last quarter. Finally, Morgan Stanley lifted its stake in Catalyst Pharmaceuticals by 59.1% in the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares during the period. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $31.49 on Wednesday. The firm has a market cap of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. The firm has a 50-day simple moving average of $31.37 and a two-hundred day simple moving average of $27.15. Catalyst Pharmaceuticals, Inc. has a one year low of $19.05 and a one year high of $32.56.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, HC Wainwright lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a report on Thursday, May 28th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).